Collaborative Arrangements - Merck Sitagliptin Catalyst Supply Agreement (Details) - USD ($) $ in Thousands |
1 Months Ended | 3 Months Ended | 9 Months Ended | |||
|---|---|---|---|---|---|---|
Dec. 31, 2015 |
Feb. 29, 2012 |
Sep. 30, 2020 |
Sep. 30, 2019 |
Sep. 30, 2020 |
Sep. 30, 2019 |
|
| Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] | ||||||
| Revenue recognized | $ 18,385 | $ 21,906 | $ 48,023 | $ 49,808 | ||
| Merck [Member] | Supply Agreement [Member] | ||||||
| Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] | ||||||
| Term of collaborative research and development agreement | 5 years | |||||
| Optional extension period | 5 years | |||||
| Merck [Member] | Supply Agreement [Member] | Product Revenue [Member] | ||||||
| Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] | ||||||
| Revenue recognized | $ 3,200 | $ 3,600 | $ 7,000 | $ 11,400 | ||
| X | ||||||||||
- Definition Collaborative Research and Development Agreement, Optional Extension Period No definition available.
|
| X | ||||||||||
- Definition Term of collaborative research and development agreement. No definition available.
|
| X | ||||||||||
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. No definition available.
|
| X | ||||||||||
- Definition Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|